A Fixed-Dose Combination Of Gemigliptin And Rosuvastatin Exhibits Similar Pharmacokinetics, Pharmacodynamics, And Safety Compared To That Of A Loose Combination In Healthy Subjects

PURPOSE: Fixed-dose combination (FDC) of gemigliptin and rosuvastatin may improve medication compliance of patients with comorbid type 2 diabetes and dyslipidemia. Pharmacokinetics (PK), pharmacodynamics (PD), and safety of gemigliptin/rosuvastatin 50/20 mg FDC was compared with a loose combination...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Eunwoo, Park, Kyoung Ryun, Jang, In-Jin, Yu, Kyung-Sang, Lee, SeungHwan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2019
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6859084/
https://www.ncbi.nlm.nih.gov/pubmed/32009778
http://dx.doi.org/10.2147/DDDT.S197054

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6859084/
https://www.ncbi.nlm.nih.gov/pubmed/32009778
http://dx.doi.org/10.2147/DDDT.S197054

Ejemplares similares